Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide in Mucosal Behçet's Syndrome
NCT05449548Recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Apr 2023
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of lenalidomide in Behçet's disease (BD), sponsored by Peking Union Medical College Hospital. Primary endpoint: Complete Remission Rate of Oral Ulcers at 12 weeks. Started Apr 2023; status: recruiting.
02
Drugs
lenalidomide
03
Conditions
Behçet's disease (BD)
Beyond the preview
Go deeper on NCT05449548.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05449548.